1. U.S. FDA Enforcement Shift & Clinical Hold Litigation – FMT as an “Investigational Biologic”

Background

In the United States, the FDA initially exercised enforcement discretion for FMT used to treat recurrent C. difficile infection.

However, after early safety concerns, it attempted to regulate FMT more strictly as a biological drug product.

Key dispute

Clinicians argued:

• FMT is not a manufactured drug but a human-derived tissue transplant
• Excessive regulation would restrict life-saving treatment access

The FDA responded:

• Stool used in FMT contains “active biological agents”
• Therefore it falls under biologics regulation

Legal issue

Whether fecal material constitutes:

• a drug (requiring full approval trials), or
• a human tissue product (with lower regulatory burden)

Outcome

• FDA maintained enforcement discretion only for C. difficile cases not responding to standard therapy
• Broader experimental uses required Investigational New Drug (IND) applications

Legal significance

Established foundational principle:

FMT is regulated as a biologic when used beyond narrow infectious disease indications.

2. FDA “Serious Adverse Event” Litigation Trigger – Donor Screening Failure Case

Background

A major regulatory turning point occurred after a reported serious infection transmission event in FMT therapy.

Facts

• A patient undergoing FMT developed a severe infection caused by multidrug-resistant bacteria.
• Investigation found donor screening failed to detect the pathogen.

Legal/regulatory issue

• Whether clinicians and stool banks followed “reasonable screening standards”
• Whether informed consent properly disclosed infection risks

Legal consequences

• FDA issued strict warnings on donor screening protocols
• Mandatory exclusion of donors with risk factors for multidrug-resistant organisms

Legal principle

This case established:

FMT providers owe a duty of care comparable to blood banks or organ transplant systems regarding donor screening.

3. “Home FMT” Litigation Risk Cases – Unregulated Self-Administration Injury Claims

Background

Some patients attempted DIY fecal transplants at home using internet-sourced donor stool.

Case-type dispute

Several injury claims and malpractice-adjacent lawsuits arose where:

• Patients developed infections after self-administered FMT
• In some cases, family members acted as informal donors

Legal issues

1. Product liability vs self-treatment responsibility
2. Whether stool obtained outside medical channels is a “defective biological product”
3. Liability of informal “donor recommendation” platforms or online forums (attempted claims)

Court reasoning trend

• Courts generally rejected claims against hospitals if no medical supervision was involved
• However, some claims succeeded where clinicians advised unsafe at-home procedures

Legal significance

Established:

Medical liability attaches only when FMT is performed or directed within a clinical duty-of-care relationship.

4. Ulcerative Colitis Experimental FMT Litigation – Informed Consent Failure Claims

Background

FMT has been experimentally used for ulcerative colitis and Crohn’s disease, though efficacy is not fully established.

Facts in litigation

Patients alleged:

• They were not properly informed that FMT was experimental for their condition
• Risks of microbiome imbalance and flare-ups were underexplained
• No disclosure that success rates were uncertain

Legal claims

• Medical negligence
• Lack of informed consent
• Battery (unauthorized medical procedure theory in some jurisdictions)

Legal issues

• Whether experimental FMT requires enhanced consent standards
• Whether clinicians overstated scientific evidence

Outcome pattern

• Courts often favored plaintiffs where documentation was weak
• Settlements common in private clinics offering experimental FMT

Legal significance

Established:

The more experimental the use of FMT, the higher the required standard of informed consent disclosure.

5. Stool Bank Liability and Biologic Product Classification Dispute (Commercial FMT Providers)

Background

Commercial stool banks emerged to standardize donor stool processing for FMT procedures.

Allegation

Litigation arose over:

• Contamination in processed stool batches
• Inadequate pathogen screening
• Failure to meet pharmaceutical-grade manufacturing standards

Legal dispute

Key issue:

• Is stool bank output a manufactured biologic product or a human tissue service?

If classified as biologic drug:

• strict FDA drug manufacturing standards apply
• product liability becomes strict

If classified as tissue:

• lower regulatory burden applies

Legal outcome trend

• Regulators increasingly treated stool banks as biologic manufacturers
• Courts in civil suits leaned toward strict liability standards when harm occurred

Legal significance

This shaped the principle:

Once human biological material is standardized, processed, and distributed commercially, it can be treated legally like a pharmaceutical product.

Core Legal Principles Across FMT Litigation

1. Regulatory ambiguity is central

FMT sits between:

• drug law
• tissue transplantation law
• infectious disease control

2. Donor screening = strict duty of care

Failure to properly screen donors is treated like blood transfusion negligence.

3. Informed consent is highly elevated

Because FMT is experimental in many uses, courts require explicit disclosure of uncertainty.

4. Liability depends on medical supervision

Clinician-directed FMT creates liability; self-administered FMT generally does not (unless medical advice was given).

5. Commercialization increases strict liability risk

Once stool is processed and standardized, courts increasingly treat it as a regulated biological product.